Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 4/2006

01-12-2006 | Review

Interleukin-6 and its receptor: from bench to bedside

Authors: Jürgen Scheller, Stefan Rose-John

Published in: Medical Microbiology and Immunology | Issue 4/2006

Login to get access

Abstract

Interleukin-6 (IL-6) is an inflammatory cytokine with a well-documented role in inflammation and cancer. The cytokine binds to a membrane bound IL-6 receptor (IL-6R) and this complex associates with two molecules of the signal transducing protein gp130 thereby initiating intracellular signaling. While gp130 is present on most if not all cells of the body, the IL-6R is only present on some cells, mainly hepatocytes and several leukocytes. Cells, which only express gp130 and no IL-6R are refractory to IL-6 signals. We have shown earlier that the IL-6R can exist as a soluble protein generated by limited proteolysis of the membrane bound receptor or by translation from an alternatively spliced mRNA. This soluble IL-6R (sIL-6R) can bind the ligand IL-6 and the soluble complex of sIL-6R and IL-6 can bind to gp130 on cells which lack the membrane bound IL-6R and trigger gp130 signaling. We have named this process ‘trans-signaling’. We will review data, which clearly show that IL-6 uses classical signaling via the membrane bound receptor and trans-signaling via the soluble receptor in various physiological and pathophysiological situations. Furthermore, we have developed designer cytokines, which can specifically enhance or inhibit IL-6 trans-signaling. These designer cytokines have been shown to be extremely useful to in therapeutic applications ranging from the long-term culture of stem cells and enhancing liver regeneration up to the blockade of chronic inflammation and cancer.
Literature
1.
2.
Hirano T, Kishimoto T (1992) Molecular biology and immunology of interleukin-6. Res Immunol 143:723–724PubMedCrossRef
3.
Grötzinger J, Kernebeck T, Kallen K-J, Rose-John S (1999) IL-6 type cytokine receptor complexes: hexamer or tetramer or both? Biol Chem 380:803–813PubMedCrossRef
4.
Grötzinger J, Kurapkat G, Wollmer A, Kalai M, Rose-John S (1997) The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins: Structure, Function, and Genetics 27:96–109CrossRef
5.
Boulanger MJ, Chow D-C, .Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 a receptor/gp130 complex. Science 300:2101–2104PubMedCrossRef
6.
Grötzinger J (2002) Molecular mechanisms of cytokine receptor activation. Biochim Biophys Acta 1592:215–223PubMedCrossRef
7.
Schroers A, Hecht O, Kallen KJ, Pachta M, Rose-John S, Grötzinger J (2005) Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Prot Sci 14:783–790CrossRef
8.
Rose-John S, Scheller J, Elson G, Jones S (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol (in press)
9.
Scheller J, Grötzinger J, Rose-John S (2006) Updating IL-6 classic- and trans-signaling. Signal Transduct (in press)
10.
Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signaling in chronic inflammation and cancer. Scand J Immunol 63:321–329PubMedCrossRef
11.
Taga T (1992) IL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130. Res Immunol 143:737–739PubMedCrossRef
12.
Müllberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23:473–480PubMed
13.
Müllberg J, Schooltink H, Stoyan T, Heinrich PC, Rose-John S (1992) Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun 189:794–800PubMedCrossRef
14.
Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96–100PubMedCrossRef
15.
Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 24:1945–1948PubMed
16.
Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027PubMed
17.
Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300:281–290PubMed
18.
Peters M, Müller A, Rose-John S (1998) Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92:3495–3504PubMed
19.
Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde KH, Rose-John S (1996) The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183:1399–1406PubMedCrossRef
20.
Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Dienes HP, Fattori E, Ciliberto G, Meyer zum Büschenfelde KH, Rose-John S (1997) Extramedullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J Exp Med 185:755–766PubMedCrossRef
21.
Schirmacher P, Peters M, Ciliberto G, Fattori E, Lotz J, Meyer zum Büschenfelde KH, Rose-John S (1998) Hepatocellular hyperplasia, plasmacytoma formation, and extracellular hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 153:639–648PubMed
22.
Peters M, Solem F, Schirmacher P, Rose-John S (2001) IL-6 and soluble IL-6R induce stem cell factor (SCF) and Flt-3 ligand expression in vivo and in vitro. Exp Hematol 29:146–155PubMedCrossRef
23.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–1869PubMedCrossRef
24.
Staskus KA, Sun R, Miller G, Racz P, Jaslowski A, Metroka C, Brett-Smith H, Haase AT (1999) Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J Virol 73:4181–4187PubMed
25.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186–1191PubMedCrossRef
26.
Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM (1996) Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88:645–656PubMed
27.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:1276–1280PubMed
28.
Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT (1997) Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71:715–719PubMed
29.
Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J et al (1997) Kaposi’s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851–1854PubMedCrossRef
30.
Berenson JR, Vescio RA (1999) HHV-8 is present in multiple myeloma patients. Blood 93:3157–3159PubMed
31.
Tarte K, Chang Y, Klein B (1999) Kaposi’s sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood 93:3159–3163PubMed
32.
Moore PS, Boshoff C, Weiss RA, Chang Y (1996) Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739–1744PubMedCrossRef
33.
Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman Kien AE, Fleckenstein B (1997) Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71:839–842PubMed
34.
Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M (1998) Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 91:1858–1863PubMed
35.
Molden J, Chang Y, You Y, Moore PS, Goldsmith MA (1997) A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 272:19625–19631PubMedCrossRef
36.
Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G (1999) Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034–4043PubMed
37.
Müllberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N, Heinz D, Galle PR, Klouche M, Rose-John S (2000) IL-6-receptor independent stimulation of human gp130 by viral IL-6. J Immunol 164:4672–4677PubMed
38.
Chow D-C, He X-L, Snow AL, Rose-John S, Garcia KC (2001) Structure of an extracellular gp130-cytokine receptor signalling complex. Science 291:2150–2155PubMedCrossRef
39.
Chatterjee M, Osborne J, Bestetti G, Yuan Chang Y, Moore PS (2002) Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298:1433–1435CrossRef
40.
Rose-John S, Schooltink H, Lenz D, Hipp E, Dufhues G, Schmitz H, Schiel X, Hirano T, Kishimoto T, Heinrich PC (1990) Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem 190:79–83PubMedCrossRef
41.
Fischer M, Goldschmitt J, Peschel C, Kallen KJ, Brakenhoff JPJ, Wollmer A, Grötzinger J, Rose-John S (1997) A designer cytokine with high activity on human hematopoietic progenitor cells. Nat Biotechnol 15:142–145PubMedCrossRef
42.
Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ (2001) Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic cells. Proc Natl Acad Sci USA 98:1757–1762PubMedCrossRef
43.
Hacker C, Kirsch RD, Ju X-S, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380–386PubMedCrossRef
44.
Ju X-S, Hacker C, Madruga J, Kurz SM, Knespel S, Blendinger G, Rose-John S, Zenke M (2003) Differentiation of human dendritic cells fron hematopoietic progenitor cells assessed by transcriptional imaging with DNA microarrays. Eur J Cell Biol 82:75–86PubMedCrossRef
45.
Hieronymus T, Gust TC, Kirsch RD, Jorgas T, Blendinger G, Goncharenko M, Rose-John S, Müller A, Zenke M (2005) Progressive and controlled development of mouse dendritic cells from Flt3+ CD11b+ progenitors in vitro. J Immunol 174:2552–2562PubMed
46.
Humphrey RK, Beattie GM, Lopez AD, Bucay N, King CC, Firpo M, Rose-John S, Hayek A (2004) Maintenance of pluripotency in human embryonic stem cells is Stat3 independent. Stem Cells 22:522–530PubMedCrossRef
47.
Viswanathan S, Benatar T, Rose-John S, Lauffenburger D, Zandstra P (2002) Maintenance of ES cell pluripotentiality is regulated by the number and types of gp130-mediated signaling complexes. Stem Cells 20:119–138PubMedCrossRef
48.
Galun E, Zeira E, Shouval D, Pappo O, Peters M, Rose-John S (2000) Liver regeneration induced by a designed hIL-6/shIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 14:1979–1987PubMedCrossRef
49.
Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Büschenfelde KH, Galle PR, Rose-John S (2000) Combined Interleukin-6 and soluble interleukin-6 receptor accelerates murine liver regeneration. Gastroenterol 119:1663–1671CrossRef
50.
Hecht N, Pappo O, Shouval D, Rose-John S, Galun E, Axelrod JH (2001) Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Therap 3:683–687CrossRef
51.
März P, Cheng J-C, Gadient RA, Patterson P, Stoyan T, Otten U, Rose-John S (1998) Sympathetic Neurons can produce and respond to interleukin-6. Proc Natl Acad Sci USA 95:3251–3256PubMedCrossRef
52.
März P, Otten U, Rose-John S (1999a) Neuronal activities of IL-6 type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 11:2995–3004CrossRef
53.
März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U (1999b) Role of interleukin-6 and soluble IL-6 receptor in region specific induction of astrocytic differentiation and neurotrophin expression. Glia 26:191–200CrossRef
54.
Schäfer KH, Mestres P, März P, Rose-John S (1999) The IL-6/sIL-6R fusion protein promotes neurite outgrowth and neuronal survival in cultured enteric neurons. J Interferon Cytokine Res 19:527–532PubMedCrossRef
55.
Sun Y, März P, Otten U, Ge J, Rose-John S (2002) The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons. Biochem Biophys Res Commun 295:532–539PubMedCrossRef
56.
Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T (1993) Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:1120–1126PubMed
57.
Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem 268:160–167PubMedCrossRef
58.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105–115PubMedCrossRef
59.
Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT, Nordan RP (2000) Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6 independent phenotype by murine plasmacytomas and hybridomas. Blood 96:3514–3521PubMed
60.
Palmer J, Ernst M, Hammacher A, Hertzog PJ 2005 Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate 62:282–289PubMedCrossRef
61.
Stuhlmann-Laeisz C, Lang S, Chalaris A, Sudarman E, Eichler J, Klingmüller U, Samuel M, Ernst M, Rose-John S, Scheller J (2006) Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine independent growth and blockade of differentiation of embryonic stem cells. Mol Biol Cell (in press)
62.
63.
Croker BA, Krebs DL, Zhang J-G, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Förster I, Clausen BE, et al (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4:540–545PubMedCrossRef
64.
Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10:739–743PubMedCrossRef
65.
Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR (2006) Ciliary neurotrophic factor reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548PubMedCrossRef
66.
Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619PubMedCrossRef
67.
Kallen K-J (2002) The role of transsignalling via the agonistic soluble IL-6 receptor. Biochim Biophys Acta 1592:323–343PubMedCrossRef
68.
Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA (2003) Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171:3202–3209PubMed
69.
Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95:8222–8226PubMedCrossRef
70.
Mihara M, Takagi N, Takeda Y, Ohsugi Y (1998) IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 112:397–402PubMedCrossRef
71.
Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187:461–468PubMedCrossRef
72.
Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–3150PubMedCrossRef
73.
Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterol 126:989–996CrossRef
74.
Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529PubMedCrossRef
75.
Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259–262PubMed
76.
Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20:247–259PubMedCrossRef
77.
Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin-6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11:1057–1064PubMedCrossRef
78.
Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, Katada Y, Yoshizaki K, Suemura M, Kishimoto T (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 42:1635–1643PubMedCrossRef
79.
de Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB (2000) Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 157:2081–2089PubMed
80.
Kyo F, Futani H, Matsui K, Terada M, Adachi K, Nagata K, Sano H, Tateishi H, Tsutsui H, Nakanishi K (2005) Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum 52:2530–2540PubMedCrossRef
81.
Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54:158–168PubMedCrossRef
82.
Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24:1510–1516PubMed
83.
Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95PubMedCrossRef
84.
Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P (1998) A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10:729–734PubMedCrossRef
85.
Robak T, Gladalska A, Stepien H, Robak E (1998) Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 7:347–353PubMedCrossRef
86.
Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Control of leukocyte infiltration during inflammation: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment. Immunity 14:705–714PubMedCrossRef
87.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C et al (2000) Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells. Nat Med 6:583–588PubMedCrossRef
88.
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S et al (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501PubMedCrossRef
89.
Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, El-Bdaoui H, Schmitt E, Bopp T, Kallen KJ, et al (2005a) The IL-6R alpha chain controls lung CD4+CD4+CD25+T regulatory cell development and function during allergic airway inflammation in vivo. J Clin Invest 115:313 –325CrossRef
90.
McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA (2005) IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102:9589–9594PubMedCrossRef
91.
Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, Yamamoto N, Ehrmann M, Williams AS, Rose-John S et al (2006) Baculovirus expression and functional characterisation of a recombinant human soluble gp130 isoform and its role in the regulation of L-6 trans-signaling. Arthritis Rheum 54:1662–1672PubMedCrossRef
92.
Doganci A, Sauer K, Karwot R, Finotto S (2005b) Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 28:257–270CrossRef
93.
Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036PubMedCrossRef
94.
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2623PubMedCrossRef
95.
Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A, Sata M (2005) A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143:125–131CrossRef
96.
Matthews V, Schuster B, Schütze S, Bußmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen K-J, Rose-John S (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278:38829–38839PubMedCrossRef
97.
Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220PubMed
98.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769PubMedCrossRef
99.
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636PubMed
100.
Hochepied T, Van Molle W, Bergeri FG, Baumann H, Libert C (2000) Involvement of the acute phase protein a1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem 275:14903–14909PubMedCrossRef
Metadata
Title
Interleukin-6 and its receptor: from bench to bedside
Authors
Jürgen Scheller
Stefan Rose-John
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 4/2006
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-006-0019-9

Other articles of this Issue 4/2006

Medical Microbiology and Immunology 4/2006 Go to the issue

Original Investigation

Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endothelial cells: small colony variants are able to survive in lysosomes

Original Investigation

Helicobacter pylori SabA adhesin evokes a strong inflammatory response in human neutrophils which is down-regulated by the neutrophil-activating protein

Original Investigation

A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice

Original Investigation

Reactivation of the Epstein–Barr virus from viral latency by an S-adenosylhomocysteine hydrolase/14-3-3 ζ/PLA2-dependent pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits